The number of drug products under development that incorporate recombinant or synthetic DNA or RNA, viral vectors, and/or genetically-modified organisms (“GMOs”) continues to grow rapidly, and several such products have received marketing approval from the FDA. This paper focuses on important points to consider when planning to initiate clinical trials with these products at sites inside or outside the USA, if the research is subject to rules and regulations of the FDA and/or the
National Institutes of Health (NIH) of the United States. In particular, we focus on the roles of Institutional Biosafety Committees (IBCs) and Institutional Review Boards (IRBs) in approving and facilitating study startup.
Most Recent Flipbooks

Targeted expertise when and where you need it: WCG CRCs equip sites to navigate the new normal
Save the Data. Protect the Patients. Prepare for What Comes Next: Remote Clinical Research Coordinators
Clinical Research Trends & Insights for 2020
16 industry experts share shifts and trends that will inform clinical research in 2020 and beyond.

Advances in Oncology Extend Lives, but Lead to New Safety Considerations for Sponsors and Investigators
From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations.

The Most Important Voice Is Missing: The Case For Including Patient Insights In Protocol Design

Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk
Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk

Part 12: Public Awareness of Clinical Research and the Path to Diversity in Clinical Trials

Part 10: Unique Challenges and Opportunities for Emerging Biopharma Companies with Focused Pipelines

Part 6: Going Remote During COVID-19: Considerations When Moving Studies Out of the Clinic Setting

Part 4: Planning for Recovery: How Research Sponsors and Research Sites are Thinking Ahead to Restart Research

Part 3: Evaluating Study Status and Leveraging Data Monitoring Committees to Make Study Decisions